What is the life expectancy of someone with Maroteaux-Lamy Syndrome?

Life expectancy for individuals with Maroteaux-Lamy syndrome, also known as Mucopolysaccharidosis type VI (MPS VI), varies significantly based on the severity of the disease and the timing of medical intervention. While historically associated with shortened lifespans, modern therapeutic advances have significantly improved prognosis, allowing many individuals to live into adulthood with a focus on symptom management and quality of life.

How does disease severity affect the prognosis of Maroteaux-Lamy syndrome?

The clinical spectrum of Maroteaux-Lamy syndrome is broad, ranging from rapidly progressing forms to more slowly progressing, attenuated phenotypes. In the severe form, symptoms often appear in early childhood, and without intervention, complications such as cardiac involvement and airway obstruction can impact longevity. Conversely, individuals with the attenuated form may experience a slower progression, often reaching adulthood with milder systemic involvement. Because Maroteaux-Lamy syndrome is a multisystem disorder, life expectancy is largely determined by the management of heart valve disease, respiratory function, and spinal cord compression.

What factors contribute to improved outcomes in Maroteaux-Lamy syndrome?

The landscape for patients with Maroteaux-Lamy syndrome has transformed over the last two decades. Early diagnosis is the most critical factor in improving long-term outcomes. Key contributors to better health and longevity include:

• Enzyme Replacement Therapy (ERT): Regular infusions of galsulfase help reduce the accumulation of glycosaminoglycans (GAGs) in tissues, which can slow the progression of visceral and skeletal symptoms.


• Multidisciplinary Care: Consistent monitoring by cardiologists, pulmonologists, and orthopedists allows for the proactive management of complications.


• Surgical Interventions: Timely procedures, such as cardiac valve replacement or decompression of the cervical spine, are essential for maintaining function.

How is quality of life prioritized alongside longevity?

For our community members living with Maroteaux-Lamy syndrome, medical experts increasingly focus on "life years" alongside "quality years." Managing pain, maintaining mobility through physical therapy, and addressing the psychosocial impacts of living with a rare, visible condition are vital. While the clinical markers of Maroteaux-Lamy syndrome are important, the goal of modern care is to ensure that patients can pursue education, careers, and meaningful relationships.

Next steps

• Consult with a metabolic specialist or a center of excellence familiar with lysosomal storage disorders.


• Connect with the 3 members of the DiseaseMaps community who share your journey for peer support.


• Maintain a comprehensive, coordinated care plan that includes annual echocardiograms and pulmonary function tests.

Medical disclaimer: This content is for informational purposes only and does not constitute professional medical advice, diagnosis, or treatment; always seek the advice of your physician regarding a medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Mucopolysaccharidosis type VI.


• Orphanet: Mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome).


• OMIM (Online Mendelian Inheritance in Man): Mucopolysaccharidosis, type VI; MPS6.


• National MPS Society: Patient resources and clinical management guidelines for Maroteaux-Lamy syndrome.